An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-Full report
Tóm tắt
Từ khóa
Tài liệu tham khảo
1978, Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events: final report of the Pooling Project, J Chronic Dis, 31, 201, 10.1016/0021-9681(78)90073-5
Stamler, 1986, Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT), JAMA, 256, 2823, 10.1001/jama.1986.03380200061022
Anderson, 1987, Cholesterol and mortality: 30 years of follow-up from the Framingham Study, JAMA, 257, 2176, 10.1001/jama.1987.03390160062027
Law, 1994, By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?, BMJ, 308, 367, 10.1136/bmj.308.6925.367
1984, The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease, JAMA, 251, 351, 10.1001/jama.1984.03340270029025
Rossouw, 1990, The value of lowering cholesterol after myocardial infarction, N Engl J Med, 323, 1112, 10.1056/NEJM199010183231606
1994, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), Lancet, 344, 1383
Shepherd, 1995, Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group, N Engl J Med, 333, 1301, 10.1056/NEJM199511163332001
Lewis, 1998, Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial, Ann Intern Med, 129, 681, 10.7326/0003-4819-129-9-199811010-00002
Downs, 1998, Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study, JAMA, 279, 1615, 10.1001/jama.279.20.1615
1998, Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels, N Engl J Med, 339, 1349, 10.1056/NEJM199811053391902
Schwartz, 2001, Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial, JAMA, 285, 1711, 10.1001/jama.285.13.1711
2002, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial, Lancet, 360, 7, 10.1016/S0140-6736(02)09327-3
Serruys, 2002, Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial, JAMA, 287, 3215, 10.1001/jama.287.24.3215
Shepherd, 2002, PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial, Lancet, 360, 1623, 10.1016/S0140-6736(02)11600-X
Holdaas, 2003, Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo controlled trial, Lancet, 361, 2024, 10.1016/S0140-6736(03)13638-0
Colhoun, 2004, Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicenter randomised placebo-controlled trial, Lancet, 364, 685, 10.1016/S0140-6736(04)16895-5
de Lemos, 2004, Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial, JAMA, 292, 1307, 10.1001/jama.292.11.1307
Grundy, 2004, Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines [Erratum in: Circulation. 2004;110:763], Circulation, 110, 227, 10.1161/01.CIR.0000133317.49796.0E
Pedersen, 2005, High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial [Erratum in: JAMA. 2005;294:3092], JAMA, 294, 2437, 10.1001/jama.294.19.2437
LaRosa, 2005, Intensive lipid lowering with atorvastatin in patients with stable coronary disease, N Engl J Med, 352, 1425, 10.1056/NEJMoa050461
Ray, 2005, Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial, J Am Coll Cardiol, 46, 1405, 10.1016/j.jacc.2005.03.077
Amarenco, 2006, High-dose atorvastatin after stroke or transient ischemic attack, N Engl J Med, 355, 549, 10.1056/NEJMoa061894
2001, Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), JAMA, 285, 2486, 10.1001/jama.285.19.2486
2002, Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report, Circulation, 106, 3143, 10.1161/circ.106.25.3143
Smith, 2011, AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation, Circulation, 124, 2458, 10.1161/CIR.0b013e318235eb4d
Catapano, 2011, ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), Atherosclerosis, 217, 3, 10.1016/j.atherosclerosis.2011.06.028
Bonow, 2002, World Heart Day 2002: the international burden of cardiovascular disease: responding to the emerging global epidemic, Circulation, 106, 1602, 10.1161/01.CIR.0000035036.22612.2B
2011
De Backer, 2003, European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice, Eur Heart J, 24, 1601, 10.1016/S0195-668X(03)00347-6
Genest, 2003, Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update, Can Med Assoc J, 169, 921
Brown, 1976, Familial hypercholesterolemia: A genetic defect in the low-density lipoprotein receptor, N Engl J Med, 294, 1386, 10.1056/NEJM197606172942509
Goldstein, 2001, Familial hypercholesterolemia, 2863
Grundy, 1990, Coronary heart disease in high-risk populations: lessons from Finland, Eur Heart J, 11, 462, 10.1093/oxfordjournals.eurheartj.a059730
Tabas, 2007, Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications, Circulation, 116, 1832, 10.1161/CIRCULATIONAHA.106.676890
Wang, 2012, The expression of IGFs and IGF binding proteins in human carotid atherosclerosis, and the possible role of IGF binding protein-1 in the regulation of smooth muscle cell proliferation, Atherosclerosis, 220, 102, 10.1016/j.atherosclerosis.2011.10.032
Falk, 2013, Update on acute coronary syndromes: the pathologists' view, Eur Heart J, 34, 719, 10.1093/eurheartj/ehs411
Chung, 1994, Liposome-like particles isolated from human atherosclerotic plaques are structurally and compositionally similar to surface remnants of triglyceride-rich lipoproteins, Arterioscler Thromb, 14, 622, 10.1161/01.ATV.14.4.622
Rapp, 1994, Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunoadsorption from human atherosclerotic plaque, Arterioscler Thromb, 14, 1767, 10.1161/01.ATV.14.11.1767
Havel, 2000, Remnant lipoproteins as therapeutic targets, Curr Opin Lipidol, 11, 615, 10.1097/00041433-200012000-00008
Veniant, 2000, Defining the atherogenicity of large and small lipoproteins containing apolipoprotein B100, J Clin Invest, 106, 1501, 10.1172/JCI10695
Twickler, 2005, Remnant lipoproteins and atherosclerosis, Curr Atheroscler Rep, 7, 140, 10.1007/s11883-005-0037-x
Varbo, 2013, Remnant cholesterol as a causal risk factor for ischemic heart disease, J Am Coll Cardiol, 61, 427, 10.1016/j.jacc.2012.08.1026
Jeppesen, 1998, Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study, Circulation, 97, 1029, 10.1161/01.CIR.97.11.1029
Lloyd-Jones, 2010, Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic impact goal through 2020 and beyond, Circulation, 121, 586, 10.1161/CIRCULATIONAHA.109.192703
Friedewald, 1972, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge, Clin Chem, 18, 499, 10.1093/clinchem/18.6.499
Cui, 2001, Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality, Arch Intern Med, 161, 1413, 10.1001/archinte.161.11.1413
Farwell, 2005, Non-high-density lipoprotein cholesterol versus low-density lipoprotein cholesterol as a risk factor for a first nonfatal myocardial infarction, Am J Cardiol, 96, 1129, 10.1016/j.amjcard.2005.06.044
Ridker, 2005, Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women, JAMA, 294, 326, 10.1001/jama.294.3.326
Liu, 2006, Non-high density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease, Am J Cardiol, 98, 1363, 10.1016/j.amjcard.2006.06.032
Holme, 2008, Relationships between lipoprotein components and risk of myocardial infarction: age, gender and short versus longer follow-up periods in the Apolipoprotein MOrtality RISk study (AMORIS), J Intern Med, 264, 30, 10.1111/j.1365-2796.2008.01925.x
Robinson, 2009, Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk, J Am Coll Cardiol, 53, 316, 10.1016/j.jacc.2008.10.024
Gordon, 1989, High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies, Circulation, 79, 8, 10.1161/01.CIR.79.1.8
Fruchart, 2008, The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia, Am J Cardiol, 102, 1K, 10.1016/j.amjcard.2008.10.002
Chapman, 2011, Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management, Eur Heart J, 332, 1345, 10.1093/eurheartj/ehr112
Teramoto, 2013, Executive Summary of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan - 2012 Version, J Atheroscler Thromb, 20, 517, 10.5551/jat.15792
Barter, 2011, HDL-C: role as a risk modifier, Atheroscler Suppl, 12, 267, 10.1016/S1567-5688(11)70885-6
1980
Blackburn, 1987, Primary prevention of coronary heart disease, Circulation, 76, I164
Pietinen, 1996, Changes in diet in Finland from 1972 to 1992: impact on coronary heart disease risk, Prev Med, 25, 243, 10.1006/pmed.1996.0053
Zhou, 2003, Nutrient intakes of middle-aged men and women in China, Japan, United Kingdom, and United States in the late 1990s: the INTERMAP study, J Hum Hypertens, 17, 623, 10.1038/sj.jhh.1001605
Knoops, 2004, Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project, JAMA, 22, 1433, 10.1001/jama.292.12.1433
Menotti, 2008, Homogeneity in the relationship of serum cholesterol to coronary deaths across different cultures: 40-year follow-up of the Seven Countries Study, Eur J Cardiovasc Prev Rehabil, 15, 719, 10.1097/HJR.0b013e328315789c
Fung, 2009, Mediterranean diet and incidence of and mortality from coronary heart disease and stroke in women, Circulation, 119, 1093, 10.1161/CIRCULATIONAHA.108.816736
Mozaffarian, 2011, Components of a cardioprotective diet: new insights, Circulation, 123, 2870, 10.1161/CIRCULATIONAHA.110.968735
Baum, 2012, Fatty acids in cardiovascular health and disease: a comprehensive update, J Clin Lipidol, 6, 216, 10.1016/j.jacl.2012.04.077
Pietinen, 2001, Nutrition and cardiovascular disease in Finland since the early 1970s: a success story, J Nutr Health Aging, 5, 150
Kok, 2004, Atherosclerosis-epidemiological studies on the health effects of a Mediterranean diet, Eur J Nutr, 43, I/2
Mensink, 2003, Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials, Am J Clin Nutr, 77, 1146, 10.1093/ajcn/77.5.1146
Grundy, 1986, Comparison of monounsaturated fatty acids and carbohydrates for lowering plasma cholesterol, N Engl J Med, 314, 745, 10.1056/NEJM198603203141204
Keys, 1984, The seven countries study: 2,289 deaths in 15 years, Prev Med, 13, 141, 10.1016/0091-7435(84)90047-1
1992, An epidemiological study of cardiovascular and cardiopulmonary disease risk factors in four populations in the Peoples Republic of China: baseline report from the P.R.C.-U.S.A. [Collaborative Study], Circulation, 85, 1083, 10.1161/01.CIR.85.3.1083
Kromhout, 2000, Saturated fat, vitamin C and smoking predict long-term population all-cause mortality rates in the Seven Countries Study, Int J Epidemiol, 29, 260, 10.1093/ije/29.2.260
Dayton, 1969, A controlled clinical trial of a diet high in unsaturated fat in preventing complications of atherosclerosis, Circulation, 40, II1
Miettinen, 1972, Effect of cholesterol-lowering diet on mortality from coronary heart-disease and other causes: a twelve-year clinical trial in men and women, Lancet, 2, 835, 10.1016/S0140-6736(72)92208-8
Gordon, 1995, Cholesterol lowering and total mortality, 333
Jenkins, 2000, Viscous and nonviscous fibres, nonabsorbable and low glycaemic index carbohydrates, blood lipids and coronary heart disease, Curr Opin Lipidol, 11, 49, 10.1097/00041433-200002000-00008
Kris-Etherton, 2008, The role of tree nuts and peanuts in the prevention of coronary heart disease: multiple potential mechanisms, J Nutr, 138, 1746S, 10.1093/jn/138.9.1746S
Banel, 2009, Effects of walnut consumption on blood lipids and other cardiovascular risk factors: a meta-analysis and systematic review, Am J Clin Nutr, 90, 56, 10.3945/ajcn.2009.27457
Fraser, 2009, Vegetarian diets: what do we know of their effects on common chronic diseases?, Am J Clin Nutr, 89, 1607S, 10.3945/ajcn.2009.26736K
Sabaté, 2010, Nut consumption and blood lipid levels: a pooled analysis of 25 intervention trials, Arch Intern Med, 170, 821, 10.1001/archinternmed.2010.79
Sofi, 2010, Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and metaanalysis, Am J Clin Nutr, 92, 1189, 10.3945/ajcn.2010.29673
van den Brandt, 2011, The impact of a Mediterranean diet and healthy lifestyle on premature mortality in men and women, Am J Clin Nutr, 94, 913, 10.3945/ajcn.110.008250
Ros, 2013, Consumption of plant seeds and cardiovascular health: epidemiologic and clinical trial evidence, Circulation, 128, 553, 10.1161/CIRCULATIONAHA.112.001119
Jenkins, 1993, Effect on blood lipids of very high intakes of fiber in diets low in saturated fat and cholesterol, N Engl J Med, 329, 21, 10.1056/NEJM199307013290104
Brown, 1999, Cholesterol-lowering effects of dietary fiber: a meta-analysis, Am J Clin Nutr, 69, 30, 10.1093/ajcn/69.1.30
Grundy, 1969, The interaction of cholesterol absorption and cholesterol synthesis in man, J Lipid Res, 10, 304, 10.1016/S0022-2275(20)43088-3
Miettinen, 1995, Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population, N Engl J Med, 333, 1308, 10.1056/NEJM199511163332002
Gylling, 1999, Cholesterol reduction by different plant stanol mixtures and with variable fat intake, Metabolism, 48, 575, 10.1016/S0026-0495(99)90053-7
Blair, 2000, Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy, Am J Cardiol, 86, 46, 10.1016/S0002-9149(00)00976-0
Katan, 2003, Stresa Workshop Participants: Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels, Mayo Clin Proc, 78, 965, 10.1016/S0025-6196(11)63144-3
Yokoyama, 2007, Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis [Erratum in: Lancet. 2007 Jul 21;370:220], Lancet, 369, 1090, 10.1016/S0140-6736(07)60527-3
Estruch, 2013, Primary prevention of cardiovascular disease with a Mediterranean diet, N Engl J Med, 368, 1279, 10.1056/NEJMoa1200303
Wolf, 1983, Influence of weight reduction on plasma lipoproteins in obese patients, Arteriosclerosis, 3, 160, 10.1161/01.ATV.3.2.160
Bays, 2013, Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association, J Clin Lipidol, 7, 304, 10.1016/j.jacl.2013.04.001
Hubert, 1983, Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study, Circulation, 67, 968, 10.1161/01.CIR.67.5.968
Park, 2012, Obesity phenotype and coronary heart disease risk as estimated by the Framingham risk score, J Korean Med Sci, 27, 243, 10.3346/jkms.2012.27.3.243
Vanhees, 2012, Importance of characteristics and modalities of physical activity and exercise in the management of cardiovascular health in individuals with cardiovascular risk factors: recommendations from the EACPR (Part II), Eur J Prev Cardiol, 19, 1005, 10.1177/1741826711430926
2009, Physical Activity Guidelines Advisory Committee report, 2008. To the Secretary of Health and Human Services. Part A. Executive summary, Nutr Rev, 67, 114
Li, 2012, Physical activity and risk of cardiovascular disease-a meta-analysis of prospective cohort studies, Int J Environ Res Public Health, 9, 391, 10.3390/ijerph9020391
Grundy, 2008, Metabolic syndrome pandemic, Arterioscler Thromb Vasc Biol, 28, 629, 10.1161/ATVBAHA.107.151092
Gami, 2007, Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies, J Am Coll Cardiol, 49, 403, 10.1016/j.jacc.2006.09.032
Mottillo, 2010, The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis, J Am Coll Cardiol, 56, 1113, 10.1016/j.jacc.2010.05.034
Orchard, 2005, The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial, Ann Intern Med, 142, 611, 10.7326/0003-4819-142-8-200504190-00009
Goldberg, 2012, Targeting the consequences of the metabolic syndrome in the Diabetes Prevention Program, Arterioscler Thromb Vasc Biol, 32, 2077, 10.1161/ATVBAHA.111.241893
Grundy, 2005, Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement [published corrections arrear in Circulation. 2005; 112:3297 and Circulation. 2005;112:e298], Circulation, 112, 2735, 10.1161/CIRCULATIONAHA.105.169404
1998, Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults: the evidence report [published correction appears in Obes Res. 1998;6:464], Obes Res, 6, 51S
2000
2003
Khan, 2006, The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: part II-therapy, Can J Cardiol, 22, 583, 10.1016/S0828-282X(06)70280-X
Graham, 2007, European guidelines on cardiovascular disease prevention in clinical practice: executive summary, Atherosclerosis, 194, 1, 10.1016/j.atherosclerosis.2007.08.024
Hara, 2006, A proposal for the cutoff point of waist circumference for the diagnosis of metabolic syndrome in the Japanese population, Diabetes Care, 29, 1123, 10.2337/dc05-2540
Oka, 2008, Reassessment of the cutoff values of waist circumference and visceral fat for identifying Japanese subjects at risk for the metabolic syndrome, Diabetes Res Clin Pract, 79, 474, 10.1016/j.diabres.2007.10.016
Zhou, 2002, Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults: study on optimal cut-off points of body mass index and waist circumference in Chinese adults, Biomed Environ Sci, 15, 83
Alberti, 2005, The metabolic syndrome-a new worldwide definition, Lancet, 366, 1059, 10.1016/S0140-6736(05)67402-8
Baigent, 2010, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials, Lancet, 376, 1670, 10.1016/S0140-6736(10)61350-5
Mihaylova, 2012, The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials, Lancet, 380, 581, 10.1016/S0140-6736(12)60367-5
Law, 2003, Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis, BMJ, 326, 1423, 10.1136/bmj.326.7404.1423
Pasternak, 2002, ACC/AHA/NHLBI clinical advisory on the use and safety of statins, J Am Coll Cardiol, 40, 567, 10.1016/S0735-1097(02)02030-2
McKenney, 2006, Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force, Am J Cardiol, 97, 89C, 10.1016/j.amjcard.2006.02.030
LaRosa, 2013, Safety and effect of very low levels of low-density lipoprotein cholesterol on cardiovascular events, Am J Cardiol, 111, 1221, 10.1016/j.amjcard.2012.12.052
Bruckert, 2005, Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study, Cardiovasc Drugs Ther, 19, 403, 10.1007/s10557-005-5686-z
Rosenbaum, 2013, Discontinuation of statin therapy due to muscular side effects: a survey in real life, Nutr Metab Cardiovasc Dis, 23, 871, 10.1016/j.numecd.2012.04.012
Parker, 2013, Effect of statins on skeletal muscle function, Circulation, 127, 96, 10.1161/CIRCULATIONAHA.112.136101
Bader, 2010, The myth of statin-induced hepatotoxicity, Am J Gastroenterol, 105, 978, 10.1038/ajg.2010.102
Sattar, 2010, Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials, Lancet, 375, 735, 10.1016/S0140-6736(09)61965-6
Preiss, 2011, Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis, JAMA, 305, 2556, 10.1001/jama.2011.860
Wagstaff, 2003, Statin-associated memory loss: analysis of 60 case reports and review of the literature, Pharmacotherapy, 23, 871, 10.1592/phco.23.7.871.32720
Golomb, 2008, Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism, Am J Cardiovasc Drugs, 8, 373, 10.2165/0129784-200808060-00004
Rojas-Fernandez, 2012, Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations, Ann Pharmacother, 46, 549, 10.1345/aph.1Q620
Bays, 2001, Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies [Erratum in: Clin Ther. 2001;23:1601], Clin Ther, 23, 1209, 10.1016/S0149-2918(01)80102-8
Cannon, 2008, Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes, Am Heart J, 156, 826, 10.1016/j.ahj.2008.07.023
Baigent, 2011, The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial, Lancet, 377, 2181, 10.1016/S0140-6736(11)60739-3
Jun, 2010, Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis, Lancet, 375, 1875, 10.1016/S0140-6736(10)60656-3
Lee, 2011, Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis, Atherosclerosis, 217, 492, 10.1016/j.atherosclerosis.2011.04.020
Frick, 1987, Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease, N Engl J Med, 317, 1237, 10.1056/NEJM198711123172001
Rubins, 1999, Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group, N Engl J Med, 341, 410, 10.1056/NEJM199908053410604
Canner, 1986, Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin, J Am Coll Cardiol, 8, 1245, 10.1016/S0735-1097(86)80293-5
Canner, 2005, Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project), Am J Cardiol, 95, 254, 10.1016/j.amjcard.2004.09.013
Brown, 2001, Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease, N Engl J Med, 345, 1583, 10.1056/NEJMoa011090
Boden, 2011, Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy, N Engl J Med, 365, 2255, 10.1056/NEJMoa1107579
ClinicalTrials.gov. HPS II THRIVE. Available at: http://clinicaltrials.gov/ct2/show/NCT00461630. Accessed January 6, 2014.
2013, HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment, Eur Heart J, 34, 1279, 10.1093/eurheartj/eht055
Jelesoff, 2006, Effectiveness and tolerability of adding ezetimibe to niacin-based regimens for treatment of primary hyperlipidemia, Endocr Pract, 12, 159, 10.4158/EP.12.2.159
Barter, 2006, Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel, J Intern Med, 259, 247, 10.1111/j.1365-2796.2006.01616.x
Lamarche, 1996, Apoprotein A-1 and B levels and the risk of ischemic heart disease during a 5 year follow-up of men in the Québec Cardiovascular Study, Circulation, 94, 273, 10.1161/01.CIR.94.3.273
Moss, 1999, Thrombogenic factors and recurrent coronary events, Circulation, 99, 2517, 10.1161/01.CIR.99.19.2517
Walldius, 2001, High apolipoprotein B, low apolipoprotein A-1, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study, Lancet, 358, 2026, 10.1016/S0140-6736(01)07098-2
Blake, 2002, Low-density lipoprotein particle concentration, and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women, Circulation, 106, 1930, 10.1161/01.CIR.0000033222.75187.B9
Rosenson, 2002, Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial, Am J Cardiol, 90, 89, 10.1016/S0002-9149(02)02427-X
Talmud, 2002, Non-fasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men, Arterioscler Thromb Vasc Biol, 22, 1918, 10.1161/01.ATV.0000035521.22199.C7
Corsetti, 2004, Apolipoprotein B determines risk for recurrent coronary events in postinfarction patients with metabolic syndrome, Atherosclerosis, 177, 367, 10.1016/j.atherosclerosis.2004.07.019
Jiang, 2004, Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes, Diabetes Care, 27, 1991, 10.2337/diacare.27.8.1991
Shai, 2004, Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women. Potential implications for clinical guidelines, Circulation, 110, 2824, 10.1161/01.CIR.0000146339.57154.9B
St-Pierre, 2005, Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men. 13-year follow-up data from the Quebec Cardiovascular Study, Arterioscler Thromb Vasc Biol, 25, 553, 10.1161/01.ATV.0000154144.73236.f4
Sniderman, 2010, Non-HDL C equals apolipoprotein B: except when it does not!, Curr Opin Lipidol, 21, 518, 10.1097/MOL.0b013e32833ee80c
Sniderman, 2011, A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk, Circ Cardiovasc Qual Outcomes, 4, 337, 10.1161/CIRCOUTCOMES.110.959247
Sniderman, 2012, Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study, Atherosclerosis, 225, 444, 10.1016/j.atherosclerosis.2012.08.039
Boekholdt, 2012, Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B Levels with risk of cardiovascular events among patients treated with statins, JAMA, 307, 1302, 10.1001/jama.2012.366
Robinson, 2012, Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and non high-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials, Am J Cardiol, 110, 1468, 10.1016/j.amjcard.2012.07.007
Barter, 2007, HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events, N Engl J Med, 357, 1301, 10.1056/NEJMoa064278
Ramjee, 2011, Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification: do the math, J Am Coll Cardiol, 58, 457, 10.1016/j.jacc.2011.05.009
Grundy, 2011, Comparisons of apolipoprotein B levels estimated by immunoassay, nuclear magnetic resonance, vertical auto profile, and non-high-density lipoprotein cholesterol in subjects with hypertriglyceridemia (SAFARI Trial), Am J Cardiol, 108, 40, 10.1016/j.amjcard.2011.03.003
Austin, 1991, Plasma triglyceride and coronary heart disease, Arterioscler Thromb, 11, 2, 10.1161/01.ATV.11.1.2
Assmann, 1996, Hypertriglyceridemia and elevated levels of lipoprotein(a) are risk factors for major coronary events in middle-aged men, Am J Cardiol, 77, 1179, 10.1016/S0002-9149(96)00159-2
Iso, 2001, Serum triglycerides and risk of coronary heart disease among Japanese men and women, Am J Epidemiol, 153, 490, 10.1093/aje/153.5.490
Austin, 1988, Low-density lipoprotein subclass patterns and risk of myocardial infarction, JAMA, 260, 1917, 10.1001/jama.1988.03410130125037
Gardner, 1996, Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women, JAMA, 276, 875, 10.1001/jama.1996.03540110029028
St-Pierre, 2001, Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease, Circulation, 104, 2295, 10.1161/hc4401.098490
Kuller, 2002, Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the Cardiovascular Health Study, Arterioscler Thromb Vasc Biol, 22, 1175, 10.1161/01.ATV.0000022015.97341.3A
Castelli, 1992, Lipids and risk of coronary heart disease. The Framingham Study, Ann Epidemiol, 2, 23, 10.1016/1047-2797(92)90033-M
Yusuf, 2004, Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study, Lancet, 364, 937, 10.1016/S0140-6736(04)17018-9
O'Donnell, 2010, Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study, Lancet, 376, 112, 10.1016/S0140-6736(10)60834-3
McLaughlin, 2003, Use of metabolic markers to identify overweight individuals who are insulin resistant, Ann Intern Med, 139, 802, 10.7326/0003-4819-139-10-200311180-00007
Bhalodkar, 2006, Accuracy of the ratio of triglycerides to high-density lipoprotein cholesterol for predicting low-density lipoprotein cholesterol particle sizes, phenotype B, and particle concentrations among Asian Indians, Am J Cardiol, 97, 1007, 10.1016/j.amjcard.2005.10.036
Bittner, 2009, The triglyceride/high-density lipoprotein cholesterol ratio predicts all-cause mortality in women with suspected myocardial ischemia: a report from the Women's Ischemia Syndrome Evaluation (WISE), Am Heart J, 157, 548, 10.1016/j.ahj.2008.11.014
Hadaegh, 2009, Triglyceride/HDL-cholesterol ratio is an independent predictor for coronary heart disease in a population of Iranian men, Nutr Metab Cardiovasc Dis, 19, 401, 10.1016/j.numecd.2008.09.003
Gasevic, 2012, The association between triglyceride to high-density-lipoprotein cholesterol ratio and insulin resistance in a multiethnic primary prevention cohort, Metabolism, 61, 583, 10.1016/j.metabol.2011.09.009
Kang, 2012, The association between the ratio of triglyceride to HDL-C and insulin resistance according to waist circumference in a rural Korean population, Nutr Metab Cardiovasc Dis, 22, 1054, 10.1016/j.numecd.2011.01.013
Nordestgaard, 2010, European Atherosclerosis Society Consensus Panel: Lipoprotein(a) as a cardiovascular risk factor: current status, Eur Heart J, 31, 2844, 10.1093/eurheartj/ehq386
Thompson, 2010, Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies, Lancet, 375, 1536, 10.1016/S0140-6736(10)60319-4
Ridker, 2007, C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus, J Am Coll Cardiol, 49, 2129, 10.1016/j.jacc.2007.02.052
Casas, 2008, C-reactive protein and coronary heart disease: a critical review, J Intern Med, 264, 295, 10.1111/j.1365-2796.2008.02015.x
Davidson, 2011, Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists, J Clin Lipidol, 5, 338, 10.1016/j.jacl.2011.07.005
Wilson, 2008, C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study, Circ Cardiovasc Qual Outcomes, 1, 92, 10.1161/CIRCOUTCOMES.108.831198
Cook, 2012, Comparison of the Framingham and Reynolds Risk scores for global cardiovascular risk prediction in the multiethnic Women's Health Initiative, Circulation, 125, 1748, 10.1161/CIRCULATIONAHA.111.075929
2012, C-reactive protein, fibrinogen, and cardiovascular disease prediction, N Engl J Med, 367, 1310, 10.1056/NEJMoa1107477
Perk, 2012, European guidelines on cardiovascular disease prevention in clinical practice (version 2012), Eur Heart J, 33, 1635, 10.1093/eurheartj/ehs092
Assmann, 2007, Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Münster (PROCAM) study, Eur J Clin Invest, 37, 925, 10.1111/j.1365-2362.2007.01888.x
Ramsay, 2011, Prediction of coronary heart disease risk by Framingham and SCORE risk assessments varies by socioeconomic position: results from a study in British men, Eur J Cardiovasc Prev Rehabil, 18, 186, 10.1177/1741826710389394
Lorenzo, 2007, The National Cholesterol Education Program - Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes, Diabetes Care, 30, 8, 10.2337/dc06-1414
Pelletier, 2009, Discordances among different tools used to estimate cardiovascular risk in postmenopausal women, Can J Cardiol, 25, e413, 10.1016/S0828-282X(09)70535-5
Patt, 2003, Assessment of global coronary heart disease risk in overweight and obese African-American women, Obes Res, 11, 660, 10.1038/oby.2003.94
Correll, 2006, Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs, J Clin Psychiatry, 67, 575, 10.4088/JCP.v67n0408
Jaumdally, 2006, Traditional risk factors for coronary atherosclerosis in Indo Asians: the need for a reappraisal, Curr Pharm Des, 12, 1611, 10.2174/138161206776843331
Franco, 2009, Trajectories of entering the metabolic syndrome: the Framingham Heart Study, Circulation, 120, 1943, 10.1161/CIRCULATIONAHA.109.855817
Wannamethee, 2008, The metabolic syndrome and cardiovascular risk in the British Regional Heart Study, Int J Obes (Lond), 32, S25, 10.1038/ijo.2008.32
Wannamethee, 2005, Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus, Arch Intern Med, 165, 2644, 10.1001/archinte.165.22.2644
Assmann, 2002, Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study, Circulation, 105, 310, 10.1161/hc0302.102575
Hense, 2003, Framingham risk function overestimates risk of coronary heart disease in men and women from Germany-results from the MONICA Augsburg and the PROCAM cohorts, Eur Heart J, 24, 937, 10.1016/S0195-668X(03)00081-2
Arai, 2013, Small dense low-density lipoproteins cholesterol can predict incident cardiovascular disease in an urban Japanese cohort: the Suita study, J Atheroscler Thromb, 20, 195, 10.5551/jat.14936
Kathiresan, 2006, Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study, Circulation, 113, 20, 10.1161/CIRCULATIONAHA.105.567107
Rumberger, 1994, Relation of coronary calcium determined by electron beam computed tomography and lumen narrowing determined by autopsy, Am J Cardiol, 73, 1169, 10.1016/0002-9149(94)90176-7
Rumberger, 1995, Coronary artery calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area. A histopathologic correlative study, Circulation, 92, 2157, 10.1161/01.CIR.92.8.2157
Budoff, 1996, Ultrafast computed tomography as a diagnostic modality in the detection of coronary artery disease: a multicenter study, Circulation, 93, 898, 10.1161/01.CIR.93.5.898
Guerci, 1997, Relation of coronary calcium score by electron beam computed tomography to arteriographic findings in asymptomatic and symptomatic adults, Am J Cardiol, 79, 128, 10.1016/S0002-9149(96)00698-4
Schmermund, 1998, Measuring the effect of risk factors on coronary atherosclerosis: coronary calcium score versus angiographic disease severity, J Am Coll Cardiol, 31, 1267, 10.1016/S0735-1097(98)00082-5
O'Leary, 1999, Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group, N Engl J Med, 340, 14, 10.1056/NEJM199901073400103
Folsom, 2008, Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: the Multi-Ethnic Study of Atherosclerosis (MESA), Arch Intern Med, 168, 1333, 10.1001/archinte.168.12.1333
Nambi, 2010, Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study, J Am Coll Cardiol, 55, 1600, 10.1016/j.jacc.2009.11.075
Wardlaw, 2009, Carotid artery imaging for secondary stroke prevention: both imaging modality and rapid access to imaging are important, Stroke, 40, 3511, 10.1161/STROKEAHA.109.557017
U-King-Im, 2009, Carotid-artery imaging in the diagnosis and management of patients at risk of stroke, Lancet Neurol, 8, 569, 10.1016/S1474-4422(09)70092-4
Grundy, 1999, Age as a risk factor: you are as old as your arteries, Am J Cardiol, 83, 1455
Greenland, 2004, Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals, JAMA, 291, 210, 10.1001/jama.291.2.210
Sung, 2008, Comparison of the coronary calcium score with the estimated coronary risk, Coron Artery Dis, 19, 475, 10.1097/MCA.0b013e3283078f9f
Elias-Smale, 2010, Coronary calcium score improves classification of coronary heart disease risk in the elderly: the Rotterdam study, J Am Coll Cardiol, 56, 1407, 10.1016/j.jacc.2010.06.029
Okwuosa, 2011, Distribution of coronary artery calcium scores by Framingham 10-year risk strata in the MESA (Multi-Ethnic Study of Atherosclerosis) potential implications for coronary risk assessment, J Am Coll Cardiol, 57, 1838, 10.1016/j.jacc.2010.11.053
Tota-Maharaj, 2012, Coronary artery calcium for the prediction of mortality in young adults < 45 years old and elderly adults > 75 years old, Eur Heart J, 33, 2955, 10.1093/eurheartj/ehs230
Yeboah, 2013, Computed tomography-derived cardiovascular risk markers, incident cardiovascular events, and all-cause mortality in nondiabetics: the Multi-Ethnic Study of Atherosclerosis, Eur J Prev Cardiol
Youssef, 2013, Coronary calcium: new insights, recent data, and clinical role, Curr Cardiol Rep, 15, 325, 10.1007/s11886-012-0325-3
Lloyd-Jones, 2004, Framingham risk score and prediction of lifetime risk for coronary heart disease, Am J Cardiol, 94, 20, 10.1016/j.amjcard.2004.03.023
Pencina, 2007, Estimating lifetime risk of developing high serum total cholesterol: adjustment for baseline prevalence and single-occasion measurements, Am J Epidemiol, 165, 464, 10.1093/aje/kwk025
Pencina, 2009, Predicting the 30-year risk of cardiovascular disease: the Framingham Heart Study, Circulation, 119, 3078, 10.1161/CIRCULATIONAHA.108.816694
Hippisley-Cox, 2010, Derivation, validation, and evaluation of a new QRISK model to estimate lifetime risk of cardiovascular disease: cohort study using Q Research database, BMJ, 341, c6624, 10.1136/bmj.c6624
Berry, 2012, Lifetime risks of cardiovascular disease, N Engl J Med, 366, 321, 10.1056/NEJMoa1012848
Lloyd-Jones, 1999, Lifetime risk of developing coronary heart disease, Lancet, 353, 89, 10.1016/S0140-6736(98)10279-9
Lloyd-Jones, 2003, Lifetime risk of coronary heart disease by cholesterol levels at selected ages, Arch Intern Med, 163, 1966, 10.1001/archinte.163.16.1966
Lloyd-Jones, 2006, Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age, Circulation, 113, 791, 10.1161/CIRCULATIONAHA.105.548206
Lloyd-Jones, 2007, Risk factor burden in middle age and lifetime risks for cardiovascular and non-cardiovascular death (Chicago Heart Association Detection Project in Industry), Am J Cardiol, 99, 535, 10.1016/j.amjcard.2006.09.099
Marma, 2010, Distribution of 10-year and lifetime predicted risks for cardiovascular disease in US adults: findings from the National Health and Nutrition Examination Survey 2003 to 2006, Circ Cardiovasc Qual Outcomes, 3, 8, 10.1161/CIRCOUTCOMES.109.869727
Allen, 2012, Impact of blood pressure and blood pressure change during middle age on the remaining lifetime risk for cardiovascular disease: the Cardiovascular Lifetime Risk Pooling Project, Circulation, 125, 37, 10.1161/CIRCULATIONAHA.110.002774
Wilkins, 2012, Lifetime risk and years lived free of total cardiovascular disease, JAMA, 308, 1795, 10.1001/jama.2012.14312
Karmali, 2013, Adding a life-course perspective to cardiovascular-risk communication, Nat Rev Cardiol, 10, 111, 10.1038/nrcardio.2012.185
Hippisley-Cox, 2008, Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2, BMJ, 336, 1475, 10.1136/bmj.39609.449676.25
Collins, 2012, Predicting the 10 year risk of cardiovascular disease in the United Kingdom: independent and external validation of an updated version of QRISK2, BMJ, 344, e4181, 10.1136/bmj.e4181
Laurier, 1994, Estimation of CHD risk in a French working population using a modified Framingham model. The PCV-METRA Group, J Clin Epidemiol, 471, 1353, 10.1016/0895-4356(94)90079-5
Liao, 1999, How generalizable are coronary risk prediction models? Comparison of Framingham and two national cohorts, Am Heart J, 137, 837, 10.1016/S0002-8703(99)70407-2
Menotti, 2000, Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study, Eur Heart J, 21, 365, 10.1053/euhj.1999.1864
D'Agostino, 2001, Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation, JAMA, 286, 180, 10.1001/jama.286.2.180
Thomsen, 2001, A new method for CHD prediction and prevention based on regional risk scores and randomized clinical trials; PRECARD and the Copenhagen Risk Score [Erratum in: J Cardiovasc Risk. 2001;8:391], J Cardiovasc Risk, 8, 291, 10.1177/174182670100800508
2002, Prediction of mortality from coronary heart disease among diverse populations: is there a common predictive function?, Heart, 88, 222, 10.1136/heart.88.3.222
Brindle, 2003, Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study, BMJ, 327, 1267, 10.1136/bmj.327.7426.1267
Empana, 2003, Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study, Eur Heart J, 24, 1903, 10.1016/j.ehj.2003.09.002
Marrugat, 2003, An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas, J Epidemiol Community Health, 57, 634, 10.1136/jech.57.8.634
Liu, 2004, Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study, JAMA, 291, 2591, 10.1001/jama.291.21.2591
Barzi, 2007, Cardiovascular risk prediction tools for populations in Asia, J Epidemiol Community Health, 61, 115, 10.1136/jech.2005.044842
Eichler, 2007, Prediction of first coronary events with the Framingham score: a systematic review, Am Heart J, 153, 722, 10.1016/j.ahj.2007.02.027
Chow, 2009, Recalibration of a Framingham risk equation for a rural population in India, J Epidemiol Community Health, 63, 379, 10.1136/jech.2008.077057
Marques-Vidal, 2009, Predictive accuracy of original and recalibrated Framingham risk score in the Swiss population, Int J Cardiol, 133, 346, 10.1016/j.ijcard.2008.01.004
Rodondi, 2012, Health ABC Study. Framingham risk score and alternatives for prediction of coronary heart disease in older adults, PLoS One, 7, e34287, 10.1371/journal.pone.0034287
Menotti, 1993, Inter-cohort differences in coronary heart disease mortality in the 25-year follow-up of the Seven Countries Study, Eur J Epidemiol, 9, 527, 10.1007/BF00209531
Campbell, 1998, Diet, lifestyle, and the etiology of coronary artery disease: the Cornell China study, Am J Cardiol, 82, 18T, 10.1016/S0002-9149(98)00718-8
Yokokawa, 2011, Serum low-density lipoprotein to high-density lipoprotein ratio as a predictor of future acute myocardial infarction among men in a 2.7-year cohort study of a Japanese northern rural population, J Atheroscler Thromb, 18, 89, 10.5551/jat.5215
Singh, 2000, Hypertension and stroke in Asia: prevalence, control and strategies in developing countries for prevention, J Hum Hypertens, 14, 749, 10.1038/sj.jhh.1001057
Hayward, 2010, Optimizing statin treatment for primary prevention of coronary artery disease, Ann Intern Med, 152, 69, 10.7326/0003-4819-152-2-201001190-00004
Cohen, 2006, Sequence variations in PCSK9, low LDL, and protection against coronary heart disease, N Engl J Med, 354, 1264, 10.1056/NEJMoa054013
Kathiresan, 2008, A PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarction, N Engl J Med, 358, 2299, 10.1056/NEJMc0707445
Ference, 2012, Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis, J Am Coll Cardiol, 60, 2631, 10.1016/j.jacc.2012.09.017
Anderson, 2013, 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult, Can J Cardiol, 29, 151, 10.1016/j.cjca.2012.11.032
Hayward, 2012, Three reasons to abandon low-density lipoprotein targets: an open letter to the Adult Treatment Panel IV of the National Institutes of Health, Circ Cardiovasc Qual Outcomes, 5, 2, 10.1161/CIRCOUTCOMES.111.964676
Ledford, 2013, Cholesterol limits lose their luster. Revised guidelines for heart health are set to remove from target-based approach, Nature, 494, 410, 10.1038/494410a
Wald, 2003, A strategy to reduce cardiovascular disease by more than 80% [Erratum in: BMJ. 2003;327:586. BMJ. 2006;60:823], BMJ, 326, 1419, 10.1136/bmj.326.7404.1419
Lonn, 2010, The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions, Circulation, 122, 2078, 10.1161/CIRCULATIONAHA.109.873232
Elley, 2012, The efficacy and tolerability of 'polypills': meta-analysis of randomised controlled trials, PLoS One, 7, e52145, 10.1371/journal.pone.0052145
Wald, 2012, Randomized polypill crossover trial in people aged 50 and over, PLoS One, 7, e41297, 10.1371/journal.pone.0041297
Yusuf, 2009, Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial, Lancet, 373, 1341, 10.1016/S0140-6736(09)60611-5
Rodgers, 2011, An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk, PLoS One, 6, e19857, 10.1371/journal.pone.0019857
Milhos, 2010, The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascular disease: a comprehensive review, Cardiol Rev, 18, 298, 10.1097/CRD.0b013e3181f52a7f
Ma, 2011, Recent development in pleiotropic effects of statins on cardiovascular disease through regulation of transforming growth factor-beta superfamily, Cytokine Growth Factor Rev, 22, 167
Porter, 2011, Statins and myocardial remodelling: cell and molecular pathways, Expert Rev Mol Med, 13, e22, 10.1017/S1462399411001931
Davignon, 2012, Pleiotropic effects of pitavastatin, Br J Clin Pharmacol, 73, 518, 10.1111/j.1365-2125.2011.04139.x
Baigent, 2005, Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [Erratum in: Lancet. 2008;371:2084. Lancet. 2005;366:1358], Lancet, 366, 1267
Misra, 2009, Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management, J Assoc Physicians India, 57, 163
Eriksson, 1997, Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise: the 6-year Malmo feasibility study, Diabetologia, 34, 891, 10.1007/BF00400196
Pan, 1997, Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study, Diabetes Care, 20, 537, 10.2337/diacare.20.4.537
Tuomilehto, 2001, Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance, N Engl J Med, 344, 1343, 10.1056/NEJM200105033441801
Knowler, 2002, Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin, N Engl J Med, 346, 393, 10.1056/NEJMoa012512
2013
Grundy, 2007, Metabolic syndrome: a multiplex cardiovascular risk factor, J Clin Endocrinol Metab, 92, 399, 10.1210/jc.2006-0513
Lichtenstein, 2006, Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee, Circulation, 114, 82, 10.1161/CIRCULATIONAHA.106.176158
2008
Daniels, 2011, Pediatric aspects of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia, J Clin Lipidol, 5, S30, 10.1016/j.jacl.2011.03.453
Goldberg, 2011, Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia, J Clin Lipidol, 5, 133, 10.1016/j.jacl.2011.03.001
Watts, 2011, Familial hypercholesterolaemia: a model of care for Australasia, Atheroscler Suppl, 12, 221, 10.1016/j.atherosclerosissup.2011.06.001
Stefanutti, 2013, Lipoprotein apheresis: state of the art and novelties, Atheroscler Suppl, 14, 19, 10.1016/j.atherosclerosissup.2012.10.021
Wiesbauer, 2009, Familial-combined hyperlipidaemia in very young myocardial infarction survivors (< or = 40 years of age), Eur Heart J, 30, 1073, 10.1093/eurheartj/ehp051
Murphy, 2013, Hypertriglyceridemia and acute pancreatitis, JAMA Intern Med, 173, 162, 10.1001/2013.jamainternmed.477
Hayward, 2006, Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem, Ann Intern Med, 145, 520, 10.7326/0003-4819-145-7-200610030-00010
Stone, 2013, 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Circulation
Civeira, 2004, Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia, Atherosclerosis, 173, 55, 10.1016/j.atherosclerosis.2003.11.010
Polonsky, 2012, Chronic kidney disease: a coronary heart disease equivalent?, Lancet, 380, 783, 10.1016/S0140-6736(12)60772-7
Adler, 2008, UKPDS-modelling of cardiovascular risk assessment and lifetime simulation of outcomes, Diabetes Med, 25, 41, 10.1111/j.1464-5491.2008.02498.x
Wannamethee, 2011, Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors, Arch Intern Med, 171, 404, 10.1001/archinternmed.2011.2
Tonelli, 2012, Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study, Lancet, 380, 807, 10.1016/S0140-6736(12)60572-8
Hoang, 2008, Global coronary heart disease risk assessment of individuals with the metabolic syndrome in the U.S, Diabetes Care, 31, 1405, 10.2337/dc07-2087
Teramoto, 2007, Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese, J Atheroscler Thromb, 14, 45, 10.5551/jat.14.45
Mascitelli, 2012, Statins for people at low risk of cardiovascular disease, Lancet, 380, 1816, 10.1016/S0140-6736(12)62025-X
Newman, 2012, Statins for people at low risk of cardiovascular disease, Lancet, 380, 1814, 10.1016/S0140-6736(12)62020-0
Brown, 2006, Biomedicine. Lowering LDL-not only how low, but how long?, Science, 311, 1721, 10.1126/science.1125884
Steinberg, 2012, The case for treating hypercholesterolemia at an earlier age: moving toward consensus, J Am Coll Cardiol, 60, 2640, 10.1016/j.jacc.2012.09.016
Domanski, 2011, Can we dramatically reduce the incidence of coronary heart disease?, Nat Rev Cardiol, 8, 721, 10.1038/nrcardio.2011.158
Kendrick, 2007, Should women be offered cholesterol lowering drugs to prevent cardiovascular disease?, BMJ, 334, 983, 10.1136/bmj.39202.397488.AD
Bukkapatnam, 2010, Statins for primary prevention of cardiovascular mortality in women: a systematic review and meta-analysis, Prev Cardiol, 13, 84, 10.1111/j.1751-7141.2009.00059.x
Ridker, 2008, Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein, N Engl J Med, 359, 2195, 10.1056/NEJMoa0807646
Grundy, 2006, Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy, Nat Rev Drug Discov, 5, 295, 10.1038/nrd2005
World Health Organization. Tobacco. Available at: http://www.who.int/mediacentre/factsheets/fs339/en/index.html. Accessed January 6, 2014.
Ezzati, 2002, Selected major risk factors and global and regional burden of disease, Lancet, 360, 1347, 10.1016/S0140-6736(02)11403-6
Gerstein, 2008, Effects of intensive glucose lowering in type 2 diabetes, N Engl J Med, 358, 2545, 10.1056/NEJMoa0802743
Jellinger, 2012, American Association of Clinical Endocrinologists' guidelines for management of dyslipidemia and prevention of atherosclerosis, Endocr Pract, 18, 1, 10.4158/EP.18.S1.1
Orchard, 2006, Type 1 diabetes and coronary artery disease, Diabetes Care, 29, 2528, 10.2337/dc06-1161
2012, Standards of medical care in diabetes-2012, Diabetes Care, 35, S11
Barylski, 2013, Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy-A meta-analysis of 11 randomized controlled trials involving 21,295 participants, Pharmacol Res, 72, 35, 10.1016/j.phrs.2013.03.007
Hou, 2013, Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis, Eur Heart J, 34, 1807, 10.1093/eurheartj/eht065
Wanner, 2005, Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis, N Engl J Med, 353, 238, 10.1056/NEJMoa043545
Sacks, 2000, Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project, Circulation, 102, 1893, 10.1161/01.CIR.102.16.1893
LaRosa, 2007, Safety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study), Am J Cardiol, 100, 747, 10.1016/j.amjcard.2007.03.102
Cannon, 2004, Intensive versus moderate lipid lowering with statins after acute coronary syndromes, N Engl J Med, 350, 1495, 10.1056/NEJMoa040583
Cannon, 2006, Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy, J Am Coll Cardiol, 48, 438, 10.1016/j.jacc.2006.04.070
Sachdeva, 2009, Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines, Am Heart J, 157, 111, 10.1016/j.ahj.2008.08.010
2006, High-dose atorvastatin after stroke or transient ischemic attack, N Engl J Med, 355, 549, 10.1056/NEJMoa061894
Kastelein, 2008, Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment, Circulation, 117, 3002, 10.1161/CIRCULATIONAHA.107.713438
Ballantyne, 2013, Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial), Am J Cardiol, 111, 506, 10.1016/j.amjcard.2012.10.037
Ginsberg, 2010, Effects of combination lipid therapy in type 2 diabetes mellitus [Erratum in N Engl J Med. 2010;6;362:1748], N Engl J Med, 362, 1563
Elam, 2011, Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective, Curr Opin Lipidol, 22, 55, 10.1097/MOL.0b013e328341a5a8
Kromhout, 2010, n-3 fatty acids and cardiovascular events after myocardial infarction, N Engl J Med, 363, 2015, 10.1056/NEJMoa1003603
Bosch, 2012, n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia, N Engl J Med, 367, 309, 10.1056/NEJMoa1203859
Inzucchi, 2012, Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), Diabetes Care, 35, 1364, 10.2337/dc12-0413
Inzucchi, 2012, Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), Diabetologia, 55, 1577, 10.1007/s00125-012-2534-0